Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vietnam Pharma Breaks Ground On $3.2 Million Drug-Production Plant

This article was originally published in PharmAsia News

Executive Summary

Vietnam's Danapha-Nanosoma pharmaceutical company began construction of a $3.2 million factory intended to produce drugs for several major diseases. The company is being aided with technology and equipment provided by a U.S.-based partner, Affordable Quality Pharmaceuticals. The plant is expected to be completed by the end of 2010, when the company plans to produce drugs to treat cancer, diabetes, heart disease and hypertension. Danapha is the parent company in the joint venture with 51 percent of the shares. (Click here for more

You may also be interested in...



RFID Tags Found To Improve Drug Supply Chain Tracking In Recent DSCSA Pilot

A pilot that used RFID tags with 2D barcodes was touted as more effective than using 2D barcodes alone in tracking drugs through the supply chain.

Emergency Clinical Trial Guidance Offers A Peak At The Future Of Virtual Trials: Expert

The current pandemic has accelerated the US FDA’s perspective on conducting remote clinical trials. The agency has published an emergency guidance to allow sponsors to continue their work, which a former FDA official says is an indication of where the agency is headed post-COVID-19.

Umbrella EUA Authorizes Surgical Masks As COVID-19 PPE

Facing ongoing shortages, the US FDA is allowing most surgical masks to be used as personal protective equipment under a new emergency use authorization.

UsernamePublicRestriction

Register

LL030495

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel